

AL Amyloidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/AB05556F4EF7EN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: AB05556F4EF7EN

Abstracts

The 7 major AL amyloidosis markets reached a value of US\$ 3,374.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 13,300.4 Million by 2034, exhibiting a growth rate (CAGR) of 13.1% during 2024-2034.

The AL amyloidosis market has been comprehensively analyzed in IMARC's new report titled "AL Amyloidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". AL amyloidosis, also referred to as primary amyloidosis, is a rare ailment characterized by the abnormal accumulation of amyloid proteins. It can cause a wide range of symptoms depending on the organs and tissues affected by the amyloid deposits. The most commonly impacted organs are the heart, kidneys, liver, and nervous system, and indications may include fatigue, shortness of breath, swelling in the legs and ankles, irregular heartbeat, chest pain, difficulty swallowing, nausea, vomiting, diarrhea, weight loss, etc. As the disease progresses, it can lead to organ failure, which can be life-threatening. The diagnosis of AL amyloidosis can be challenging, as its symptoms are often non-specific and can mimic other common conditions. Physicians typically start with a thorough medical history and physical exam, followed by blood and urine tests to look for abnormal protein levels and evidence of organ damage. A biopsy of affected tissue is usually necessary to confirm the presence of amyloid fibrils and to determine the specific type of amyloidosis. Several imaging tests, such as echocardiograms and CT scans, may also be used to evaluate the extent of organ involvement.

The increasing cases of mutations in the DNA of plasma cells and the rising incidence of underlying plasma cell disorders, such as multiple myeloma and monoclonal gammopathy of undetermined significance, are primarily driving the AL amyloidosis

market. In addition to this, the widespread adoption of amyloid stabilizers, which stabilize the amyloid protein and prevent it from accumulating in tissues and organs, for treating the ailment is further bolstering the market growth. Moreover, the escalating utilization of novel agents, including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, etc., which target the underlying mechanisms of AL amyloidosis, has significantly improved response rates and prolonged progression-free survival in patients. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of high-dose chemotherapy, followed by autologous stem cell transplantation, as a treatment option for eligible patients with AL amyloidosis is also propelling the market growth. This procedure aims to eliminate abnormal cells that produce the amyloid protein and improve organ function. Furthermore, the ongoing advancements in diagnostic techniques, such as the introduction of serum-free light chain assays and mass spectrometry, have facilitated earlier diagnosis, allowing for prompt initiation of treatment and better management of disease-related complications. This, in turn, is expected to drive the AL amyloidosis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the AL amyloidosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for AL amyloidosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the AL amyloidosis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the AL amyloidosis market
Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the AL amyloidosis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current AL amyloidosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the AL amyloidosis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the AL amyloidosis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the AL amyloidosis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of AL amyloidosis across the seven major markets?

What is the number of prevalent cases (2018-2034) of AL amyloidosis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of AL amyloidosis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with AL amyloidosis across the seven major markets?

What is the size of the AL amyloidosis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of AL amyloidosis?

What will be the growth rate of patients across the seven major markets?

AL Amyloidosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for AL amyloidosis drugs across the seven

major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the AL amyloidosis market?

What are the key regulatory events related to the AL amyloidosis market?

What is the structure of clinical trial landscape by status related to the AL amyloidosis market?

What is the structure of clinical trial landscape by phase related to the AL amyloidosis market?

What is the structure of clinical trial landscape by route of administration related to the AL amyloidosis market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 AL AMYLOIDOSIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 AL AMYLOIDOSIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 AL AMYLOIDOSIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 AL AMYLOIDOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 AL AMYLOIDOSIS - UNMET NEEDS

10 AL AMYLOIDOSIS - KEY ENDPOINTS OF TREATMENT

11 AL AMYLOIDOSIS - MARKETED PRODUCTS

- 11.1 List of AL Amyloidosis Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Darzalex Faspro (Daratumumab/hyaluronidase) - Janssen Biotech
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 AL AMYLOIDOSIS - PIPELINE DRUGS

12.1 List of AL Amyloidosis Pipeline Drugs Across the Top 7 Markets

12.1.1 CAEL-101 - Caelum Biosciences

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 NEOD 001 - Prothena

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

12.1.3 ZN d5 - Zentera Therapeutics

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

12.1.4 STI-6129 - Sorrento Therapeutics

12.1.4.1 Drug Overview

12.1.4.2 Mechanism of Action

12.1.4.3 Clinical Trial Results

12.1.4.4 Safety and Efficacy

12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. AL AMYLOIDOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. AL AMYLOIDOSIS – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 AL AMYLOIDOSIS - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 AL Amyloidosis - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 AL Amyloidosis - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 AL Amyloidosis - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 AL Amyloidosis - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 AL Amyloidosis - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 AL Amyloidosis - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 AL Amyloidosis - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 AL Amyloidosis - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 AL Amyloidosis - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 AL Amyloidosis - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 AL Amyloidosis - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 AL Amyloidosis - Market Size

15.6.1.1 Market Size (2018-2023)

- 15.6.1.2 Market Forecast (2024-2034)
- 15.6.2 AL Amyloidosis - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 AL Amyloidosis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 AL Amyloidosis - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 AL Amyloidosis - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 AL Amyloidosis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 AL Amyloidosis - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 AL Amyloidosis - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 AL Amyloidosis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 AL Amyloidosis - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 AL Amyloidosis - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 AL Amyloidosis - Access and Reimbursement Overview

16 AL AMYLOIDOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 AL AMYLOIDOSIS MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 AL AMYLOIDOSIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: AL Amyloidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/AB05556F4EF7EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AB05556F4EF7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

